Cargando…

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

RON (recepteur d'origine nantais) and MET (hepatocyte growth factor receptor) are tyrosine kinase receptors. Various cancers have aberrant RON and MET expression and activation, which contribute to cancer cell proliferation, invasiveness, and metastasis. Here, we explored RON and MET expression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Chen-Yu, Xu, Xiang-Ming, Hong, Bo, Wu, Zhi-Gang, Qian, Yun, Weng, Tian-Hao, Liu, Yi-Zhi, Tang, Tao-Ming, Wang, Ming-Hai, Yao, Hang-Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906148/ https://www.ncbi.nlm.nih.gov/pubmed/31867280 http://dx.doi.org/10.3389/fonc.2019.01377

Ejemplares similares

RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer
por: Weng, Tian-Hao, et al.
Publicado: (2020)

MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy
por: Yao, Hang-Ping, et al.
Publicado: (2020)

Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160
por: Lu, Yi, et al.
Publicado: (2008)

Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction
por: Wang, Ming-Hai, et al.
Publicado: (2013)

Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer
por: Kanteti, Rajani, et al.
Publicado: (2014)

Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody–drug conjugates as lead drug candidates for clinical trials
por: Yao, Hang-Ping, et al.
Publicado: (2020)

Autoinhibition of the Ron receptor tyrosine kinase by the juxtamembrane domain
por: Wang, Xin, et al.
Publicado: (2014)

An Introduction and Overview of RON Receptor Tyrosine Kinase Signaling
por: Hunt, Brian G., et al.
Publicado: (2023)

Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy
por: Yao, Hang-Ping, et al.
Publicado: (2019)

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase
por: Yao, Hang-Ping, et al.
Publicado: (2021)

Correction to: Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy
por: Yao, Hang-Ping, et al.
Publicado: (2019)

Regulation of Macrophage Polarization by RON Receptor Tyrosine Kinase Signaling
por: Chaudhuri, Amitabha
Publicado: (2014)

Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets
por: Chang, Katherine, et al.
Publicado: (2015)

The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells
por: Yao, Hang-Ping, et al.
Publicado: (2011)

RON tyrosine kinase mutations in brain metastases from lung cancer
por: Milan, Melissa, et al.
Publicado: (2018)

Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase
por: Ma, Qi, et al.
Publicado: (2010)

A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells
por: Chakedis, Jeffery, et al.
Publicado: (2015)

Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib
por: Wu, Wen-Chi, et al.
Publicado: (2023)

The Receptor Tyrosine Kinase RON and Its Isoforms as Therapeutic Targets in Ewing Sarcoma
por: Berning, Philipp, et al.
Publicado: (2020)

RON is not a prognostic marker for resectable pancreatic cancer
por: Tactacan, Carole M, et al.
Publicado: (2012)

Variant RONΔ160 of the RON receptor tyrosine kinase promotes the growth and invasion in vitro and in vivo in gastric cancer cell lines
por: Zhou, Dong-Hui, et al.
Publicado: (2015)

OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase
por: Hao, Chengcheng, et al.
Publicado: (2019)

Expression of the RON receptor tyrosine kinase and its association with gastric carcinoma versus normal gastric tissues
por: Zhou, Donghui, et al.
Publicado: (2008)

Ribosomal Protein S6 Kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein
por: Ma, Qi, et al.
Publicado: (2011)

Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy
por: Tong, Xiang-Min, et al.
Publicado: (2019)

Crystal Structure of the Sema-PSI Extracellular Domain of Human RON Receptor Tyrosine Kinase
por: Chao, Kinlin L., et al.
Publicado: (2012)

The MST1R/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies
por: Cazes, Alex, et al.
Publicado: (2022)

Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder
por: Cheng, H-L, et al.
Publicado: (2005)

Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines
por: Zhao, S, et al.
Publicado: (2013)

THE RON RECEPTOR TYROSINE KINASE POSITIVELY REGULATES ANGIOGENIC CHEMOKINE PRODUCTION IN PROSTATE CANCER CELLS
por: Thobe, Megan N., et al.
Publicado: (2009)

Evidence for 2-Methoxyestradiol-Mediated Inhibition of Receptor Tyrosine Kinase RON in the Management of Prostate Cancer
por: Batth, Izhar Singh, et al.
Publicado: (2021)

MicroRNA Expression Profiling of Lung Cancer with Differential Expression of the RON Receptor Tyrosine Kinase
por: Ou, Huilin, et al.
Publicado: (2021)

Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
por: Qin, Anna, et al.
Publicado: (2023)

Ron Knockdown and Ron Monoclonal Antibody IMC-RON8 Sensitize Pancreatic Cancer to Histone Deacetylase Inhibitors (HDACi)
por: Zou, Yi, et al.
Publicado: (2013)

Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers
por: Tao, Zhonghua, et al.
Publicado: (2021)

12-05-2009 14 38 Interview met Ron Howard,...
Publicado: (2009)

Expression and Prognostic Evaluation of the Receptor Tyrosine Kinase MET in Canine Malignant Melanoma
por: Koo, Karen, et al.
Publicado: (2023)

The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells
por: Feres, K.J., et al.
Publicado: (2008)

Neuroprotective Role of the Ron Receptor Tyrosine Kinase Underlying Central Nervous System Inflammation in Health and Disease
por: Dey, Adwitia, et al.
Publicado: (2018)

The RON Receptor Tyrosine Kinase Promotes Metastasis by Triggering MBD4-Dependent DNA Methylation Reprogramming
por: Cunha, Stéphanie, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ucl0jgl5cp19pqjnql3tc9n0sm